Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May;13(5):3638-3640.
doi: 10.3892/ol.2017.5922. Epub 2017 Mar 27.

Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells

Lin Hao  1 , Yan Zhao  1 , Zhi-Gang Li  1 , Hou-Guang He  1 , Qing Liang  1 , Zhi-Guo Zhang  1 , Zhen-Duo Shi  1 , Pei-Ying Zhang  1 , Cong-Hui Han  1
Affiliations

Tumor necrosis factor-related apoptosis-inducing ligand inhibits proliferation and induces apoptosis of prostate and bladder cancer cells

Lin Hao et al. Oncol Lett. 2017 May.

Abstract

The effect of recombinant and purified tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) on the proliferation and apoptosis of PC-3 prostate cancer cells and the 5637 bladder cancer cells were investigated. We used a cell proliferation assay and flow cytometry to measure the proliferation and apoptosis of cancer cells after 24-h incubation of PC-3 and 5637 cells with different concentrations of TRAIL. PC-3 cell proliferation rate significantly decreased when TRAIL was used at concentrations of 20, 40, 80 and 160 ng/ml compared with the untreated group. In the 5637 cells, the proliferation rate significantly decreased when TRAIL was used at concentrations of 5, 10, 20 and 40 ng/ml compared with the untreated group. The flow cytometry results also confirmed that the apoptosis rate of both cancer cell lines increased with TRAIL protein concentration. In conclusion, recombinant and purified TRAIL has anticancer activity by inhibiting proliferation and promoting apoptosis of prostate and bladder cancer cells.

Keywords: apoptosis; bladder cancer; proliferation; prostate cancer; tumor necrosis factor-related apoptosis-inducing ligand.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Detection of 5637 cell apoptosis by flow cytometry. Apoptosis increased with the concentration of TRAIL. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
Figure 2.
Figure 2.
Detection of PC-3 cell apoptosis by flow cytometry. Apoptosis increased with the concentration of TRAIL. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. doi: 10.3322/caac.21149. - DOI - PubMed
    1. Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, et al. European Association of Urology: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64:639–653. doi: 10.1016/j.eururo.2013.06.003. - DOI - PubMed
    1. Seiler R, Thalmann GN, Fleischmann A, Shariat SF, van Rhijn BW, Comperat E, Sylvester RJ, Kaasinen E, Bohle A, Palou RJ, et al. MMP-2 and MMP-9 in lymph-node-positive bladder cancer. J Clin Pathol. 2011;64:1078–1082. doi: 10.1136/jclinpath-2011-200153. - DOI - PubMed
    1. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, Novotny W, Goldwasser MA, Tohnya TM, Lum BL, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28:2839–2846. doi: 10.1200/JCO.2009.25.1991. - DOI - PubMed
    1. Galligan L, Longley DB, McEwan M, Wilson TR, McLaughlin K, Johnston PG. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005;4:2026–2036. doi: 10.1158/1535-7163.MCT-05-0262. - DOI - PubMed